SIMCERE PHARMA (02096) has seen a surge of over 4%, currently up 3.47% at HKD 13.42, with a trading volume of HKD 89.99 million. According to an announcement from the company’s official WeChat, on October 16, SIMCERE’s oncology innovation subsidiary, SIMCERE Innovative Medicines, partnered with U.S. biotech firm NextCure, Inc. to announce the completion of the first U.S. patient enrollment in the Phase I clinical trial (NCT06792552) of SIM0505 for patients with advanced solid tumors. The study aims to assess the drug's safety, tolerability, pharmacokinetics, and efficacy. SIM0505 is a novel antibody-drug conjugate (ADC) developed by SIMCERE Innovative Medicines targeting CDH6 (calcium adhesion molecule-6 or K-cadherin). It boasts a unique binding epitope with a higher affinity for tumor antigens than competing candidates. Additionally, SIM0505 utilizes SIMCERE's proprietary TOPoisomerase I inhibitor (TOPOi) payload, which not only provides strong anti-tumor activity but also exhibits high systemic clearance, thereby expanding the therapeutic window. Following the initiation of the dose-escalation study in China, NextCure has extended the trial to the U.S., starting to enroll patients in the mid-dose group, with plans for continued progress in both China and the U.S. NextCure has secured exclusive global rights for SIM0505 outside the Greater China region.